drugset

drugset / Trial / NCT06002659

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

NCT06002659 ↗

Phase 1/2 Recruiting 18 enrolled Uppsala University Elicera Therapeutics · collab Karolinska University Hospital · collab Uppsala University Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.

Timeline

Start: 2024-05-01
Primary completion: 2027-12-30
Completion: 2027-12-30

Publications

Background Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng. 2022 Jul;6(7):830-841. doi: 10.1038/s41551-022-00875-5. Epub 2022 Apr 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR20(NAP)-T	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—

Indications